PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
65.30%
Net income growth above 1.5x VET's 1.91%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-17.65%
Negative yoy D&A while VET is 57.19%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-114.24%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-100.00%
Negative yoy SBC while VET is 6.21%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
219.33%
Well above VET's 78.77% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
-13.33%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
219.33%
Growth well above VET's 78.77%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
321.37%
Operating cash flow growth below 50% of VET's 1408.30%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-39.29%
Negative yoy CapEx while VET is 26.08%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
442.86%
Some acquisitions while VET is negative at -129.20%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
229.04%
Purchases growth of 229.04% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-73.02%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-39.29%
We reduce yoy other investing while VET is 95.08%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
52.61%
Investing outflow well above VET's 65.71%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-383.33%
We cut debt repayment yoy while VET is 7.31%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.